Due to the compound makeup of the cannabis plant; it might be even easier to gain regulatory approval of cannabinoid drugs than it’d be for ‘broad spectrum’ extracts already on the market. The is because Cannabinoid self-isolates, thus making synthetic preparations of cannabinoids easier to characterize as a simple, single cannabinoid molecule-type.
However, another compound, Cannabigerol(CBG, unlike CBD, has a somewhat weaker affinity for the body’s cannabinoid receptors. In comparison; CBG is thought to draw out most of its health benefits through a stronger, direct interaction with the body’s receptors. As a result, CBG is thought to be a more suitable buffer for some of the psychoactive effects of tetrahydrocannabinol (THC).
In terms of regulation and marketing, Europe might have found a way to justify its cannabinoid sales already. According to the EU ‘products for human consumption, extracts of Cannabis sativa and derived products containing cannabinoids, as well as synthetic cannabinoids are considered ‘novel foods’.
A novel food is defined as any food or ingredient that has not been consumed to a significant degree by humans in the EU before 15 May 1997. Not to mention, The Novel Food Regulation (EU) 2015/228322 includes an application procedure (for foods and food ingredients that are fully novel) as well as a notification procedure (simplified application for traditional foods with a safe history of use in one or more countries.
The vast potential of the CBD and cannabinoid market is further emphasized by the recent study by the Association for the Cannabinoid Industry (ACI). Predicted by the ACI, sales of CBD products in 2021 will peak at 690 million pounds in the UK alone. The CBG market might share a similar fate.